Chih-An Shih

Dr. Chih-An Shih

Pingtung Hospital, Pingtung City, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
CSChih-An Shih
Chih-An Shih
DWDeng-Chyang Wu
Deng-Chyang Wu
CSChang-Bih Shie
Chang-Bih Shie
PHPing-I Hsu
Ping-I Hsu
Due to the increasing prevalence of antimicrobial resistance, the efficacy of standard triple therapy for Helicobacter pylori (H. pylori) infection has declined, with eradication rates now falling below 80% in most countries. Although bismuth quadruple therapy and concomitant therapy are advised in regions with high clarithromycin resistance, these treatments commonly cause frequent adverse events and require the use of two or three antibiotics. This review article evaluates the effectiveness of 14-day mono-antibiotic therapies for H. pylori infection through randomized controlled trials conducted from 1 October 2014 to 1 October 2024. The pooled eradication rates for 14-day high-dose amoxicillin/proton pump inhibitor (PPI) dual therapies were 86.1% (3335/3875; 95% confidence interval (CI): 85.1–87.2%) by intention-to-treat (ITT) analysis and 87.3% (3232/3702; 95% CI: 86.2–88.4%) by per-protocol (PP) analysis. For 14-day high-dose amoxicillin/vonoprazan dual therapies, the rates were 87.4% (1085/1241; 95% CI: 85.5–89.2%) by ITT and 93.0% (1044/1124; 95% CI: 91.5–94.5%) by PP. In the penicillin-allergic population, 14-day tetracycline/vonoprazan dual therapy showed eradication rates of 92.0% (138/150) by ITT and 95.1% (135/142) by PP. In conclusion, 14-day tetracycline/vonoprazan dual therapy presents an effective option for eradicating H. pylori in patients allergic to penicillin. For those without a penicillin allergy, first-line treatments can include 14-day mono-antibiotic regimens, such as high-dose amoxicillin/PPI dual, high-dose amoxicillin/vonoprazan dual, and tetracycline/vonoprazan dual therapies.

16 June 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PHPing-I Hsu
Ping-I Hsu
CCChien-Lin Chen
Chien-Lin Chen
CSChih-An Shih
Chih-An Shih
KCKuan-Yang Chen
Kuan-Yang Chen
WTWei-Chen Tai
Wei-Chen Tai
DWDeng-Chyang Wu
Deng-Chyang Wu
INTRODUCTION: The aim of this study was to compare the efficacy of 14-day vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid therapies for the first-line treatment of Helicobacter pylori infection. METHODS: In the multicenter, randomized, open-label trial, we consecutively recruited adult H. pylori -infected patients from 6 centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day vonoprazan high-dose dual, vonoprazan triple, or rabeprazole reverse hybrid therapy. Eradication status was determined by 13 C-urea breath test. The primary outcome was the eradication rate of H. pylori assessed in the intention-to-treat population. RESULTS: Between December 2021 and April 2024, 906 patients were recruited. The eradication rates were 83.8% (253/302) for vonoprazan high-dose dual therapy, 90.1% (272/302) for vonoprazan triple therapy, and 89.1% (271/302) for rabeprazole reverse hybrid therapy in intention-to-treat analysis. Vonoprazan high-dose dual therapy was inferior to both vonoprazan triple (95% confidence interval −11.5% to −1.1%; P = 0.022) and rabeprazole reverse hybrid therapies (95% confidence interval −10.7% to 0.1%; P = 0.031). There were no significant differences in the overall proportions of patients experiencing adverse events among vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid groups (10.3%, 15.2%, and 15.6%, respectively). Body weight ≥60 kg, clarithromycin resistance, and poor drug adherence were independent risk factors predicting eradication failure for the 3 corresponding therapies, with odds ratios of 3.2 (1.3–7.5), 4.8 (1.2–18.9), and 14.8 (2.8–78.8), respectively. DISCUSSION: Vonoprazan triple therapy and rabeprazole reverse hybrid therapy are preferable to vonoprazan dual therapy for the first-line treatment of H. pylori infection.

17 March 2022 in Medicina
Verified
Journal Article
Open access
PDF file
JHJui-Ting Hsu
Jui-Ting Hsu
PHPing-I Hsu
Ping-I Hsu
CSChang-Bih Shie
Chang-Bih Shie
SCSeng-Kee Chuah
Seng-Kee Chuah
IWI-Ting Wu
I-Ting Wu
CSChih-An Shih
Chih-An Shih
Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs are often accompanied by concurrent infection, low compliance, substance abuse, and risky behavior. The aim of the study is to compare the efficacies of direct-acting antiviral (DAA) therapy for HCV infection in PWIDs and those without opioid injection. Materials and Methods: In this retrospective cohort study, we included 53 PWIDs with HCV infections treated on site in a methadone program and 106 age- and sex-matched patients with HCV infections who had no history of opioid injection (ratio of 1:2). All eligible subjects received anti-HCV treatment by DAA agents in our hospital from March 2018 to December 2020. The charts of these patients were carefully reviewed for demographic data, types of DAA agents, and treatment outcomes. The primary outcome measure was sustained virological response (SVR). Results: PWIDs and non-drug users had different HCV genotype profiles (p = 0.013). The former had higher proportions of genotype 3 (18.9% vs. 7.5%) and genotype 6 (24.5% vs. 14.2%) than the latter. The two patient groups had comparable rates of complete drug refilling (100.0% vs. 91.1%) and frequency of loss to follow-up (3.8% vs. 0.9%). However, PWIDs had a lower SVR rate of DAA treatment than non-drug users (92.2% vs. 99.0%; p = 0.04). Further analysis showed that both human immunodeficiency virus (HIV) coinfection and history of PWID were risk factors associated with treatment failure. The subjects with coinfection with HIV had lower SVR rates than those without HIV infection (50.0% vs. 96.5%; p = 0.021). Conclusions: PWIDs with HCV infections have higher proportions of HCV genotype 3 and genotype 6 than non-drug users with infections. DAA therapy can achieve a high cure rate (>90%) for HCV infection in PWID, but its efficacy in PWID is lower than that in non-drug users.

10 March 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
CSChih-An Shih
Chih-An Shih
IWI-Ting Wu
I-Ting Wu
DWDeng-Chyang Wu
Deng-Chyang Wu
WLWei-Yi Lei
Wei-Yi Lei
FTFeng-Woei Tsay
Feng-Woei Tsay
PHPing-I Hsu
Ping-I Hsu
Mono-antibiotic therapy for Helicobacter pylori (H. pylori) infection minimizes unnecessary antibiotic exposure, reduces disruption of the gut microbiota, and lowers the risk of multidrug resistance. Although resistance of H. pylori to amoxicillin remains extremely low (<3%) worldwide, regular-dose amoxicillin monotherapy achieves eradication rates of less than 30%. Strategies to improve the efficacy of amoxicillin-based mono-antibiotic therapy include elevating intragastric pH with potent acid suppression, increasing the amoxicillin dose, and adding bismuth salts to the treatment regimen. This review evaluates the safety and effectiveness of six amoxicillin-based treatments for H. pylori. All regimens lasted 14 days and were studied in clinical trials published between 1 October 2014, and 1 October 2025. The pooled intention-to-treat and per-protocol eradication rates for each regimen were as follows: Regimen 1: Regular-dose amoxicillin + high-dose proton pump inhibitor (PPI): 84.7% (83/98) and 84.7% (83/98); Regimen 2: High-dose amoxicillin + high-dose PPI: 85.3% (3709/4347) and 89.9% (3692/4109); Regimen 3: Regular-dose amoxicillin + high-dose potassium-competitive acid blocker (PCAB): 86.0% (901/1048) and 91.2% (888/974); Regimen 4: High-dose amoxicillin + high-dose PCAB: 88.2% (1771/2009) and 93.5% (1720/1839); Regimen 5: Regular-dose amoxicillin + high-dose PCAB + bismuth: 84.9% (327/385) and 91.3% (327/358); Regimen 6: High-dose amoxicillin + high-dose PCAB + bismuth: 95.8% (115/120) and 98.4% (115/117). In conclusion, potent acid inhibition, escalation of amoxicillin dosage, and incorporation of bismuth can transform amoxicillin mono-antibiotic therapy from an ineffective approach into a highly effective eradication regimen for H. pylori infection.

26 October 2025 in Advances in Digestive Medicine
Verified
Journal Article
Closed access
PHPing-I Hsu
Ping-I Hsu
DWDeng-Chyang Wu
Deng-Chyang Wu
SCSeng-Kee Chuah
Seng-Kee Chuah
KYKai‐Chun Yang
Kai‐Chun Yang
CKChao‐Hung Kuo
Chao‐Hung Kuo
FTFeng‐Woei Tsay
Feng‐Woei Tsay

22 November 2023 in Advances in Digestive Medicine
Verified
Journal Article
Closed access
CSChih-An Shih
Chih-An Shih
SCSeng-Kee Chuah
Seng-Kee Chuah
PHPing-I Hsu
Ping-I Hsu
CLChing‐Liang Lu
Ching‐Liang Lu
SKSung‐Shuo Kao
Sung‐Shuo Kao
DWDeng‐Chyang Wu
Deng‐Chyang Wu